After purchasing 2,076 additional shares, the firm now owns 4,823 shares. Financial Insights Inc. held BioMarin Pharmaceutical stock worth $499,000.
BMRN shares have been bought and sold by a number of institutional investors. Arlington Capital Management Inc. purchased a new stake of BioMarin pharmaceutical shares in the fourth quarter, worth approximately $1,150,000. Abrdn plc increased its holdings of BioMarin pharmaceutical by 6.8% in the fourth quarter. Abrdn Plc owns 17,629 of the biotechnology firm's shares worth $1,824,000. It acquired an additional 1,122 during the period. Qsemble Capital Management LP purchased a new stake of BioMarin pharmaceutical shares worth $838,000. Bank of Nova Scotia increased its holdings of BioMarin Pharma by 4,981.1% in the fourth quarter. Bank of Nova Scotia owns 216 049 shares of BioMarin Pharmaceutical stock, worth $22,359,000, after purchasing an additional 211 797 shares. Great Lakes Advisors LLC also acquired shares of BioMarin Pharma during the fourth quarter, worth $249,000. BMRN was the subject of many research reports. Guggenheim reduced their target price for BioMarin Pharmaceutical on Thursday, April 27, from $125.00 down to $120.00. In a research report published on Thursday, BioMarin Pharmaceutical shares were covered. They gave the company a rating of 'buy.' Sanford C. Bernstein began covering BioMarin Pharmaceutical shares in a research report on Tuesday, 21st March. The company was given an 'underperform rating' and a price target of $81.00. SVB Leerink raised their price target on BioMarin Pharmaceutical shares from $120.00 to $130.00 in a research report on Friday, Feb. 3rd. They also gave the stock an "outperform" rating. Seven analysts have given the stock a hold recommendation, while twelve others have recommended that the company be bought. According to MarketBeat data, BioMarin Pharmaceutical has a current consensus rating of "Moderate buy" and an average price target of $118.65.
Insiders Bet on the Future
On Monday, 13th March, 8,000 shares were sold. Stock was sold for $723,600.00 at an average price $90.45. The chief executive now owns directly 487,856 company shares, worth $44,126.575.20. In a deal dated March 13th, 8,000 BioMarin Pharmaceutical shares were sold. Stock was sold for $723,600.00 at an average of $90.45. After the completion of this transaction, the CEO now owns directly 487,856 of the company's shares, valued at $44,126.575.20. In a deal dated April 3, 2008, the company sold 8,500 shares. The shares were purchased at an average of $97.09 for a value of $825.265.00. After the sale, the director owns 28,950 company shares, worth approximately $2,810 755.50. Insiders sold 81.500 shares of stock worth $7.735,465. Insiders own 1.84%.
BioMarin Pharmaceuticals Trading down 0.4 %
The stock fell $0.33 in the trading hours of Friday to $91.90. The trading volume was 766,254 compared to the average of 1,105762. The market cap is $17.25 billion. It has a P/E ratio of 241.84 with a beta value of 0.38. The company's quick ratio is 3.21, its current ratio is 4.75 and its debt-to equity ratio is 0.23. The company's simple moving 50-day average is $94,77, and its simple 200-day average is $99,76. BioMarin Pharma Inc.'s one-year low is $70.73 while its one-year high is $117.77.
The last time the company released its results was on February 27th. The biotechnology firm reported $0.11 per share for the quarter. This was below the consensus estimate ($0.01) of $0.12. BioMarin Pharmaceutical reported a return of equity of 4.02%, and a margin net of 3.30%. Revenue for the quarter was $537.54m, which is higher than analyst expectations of $533.88m. Analysts predict on average that BioMarin Pharma Inc. will earn 1.06 EPS in the current fiscal period.
BioMarin Pharmaceutical Company profile
BioMarin Pharmaceutical, Inc is a company that develops and markets therapies for serious and life-threatening medical conditions and rare diseases. The company's pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307 John C. Klock and Christopher M.
MarketBeat.com offers a FREE daily email newsletter